Replimune Group (NASDAQ:REPL) Price Target Raised to $27.00 at BMO Capital Markets

Replimune Group (NASDAQ:REPL) had its price objective hoisted by BMO Capital Markets from $18.00 to $27.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research firms have also weighed in on REPL. HC Wainwright raised their price target on shares of Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday. Jefferies Financial Group upped their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. lifted their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus price target of $19.14.

Replimune Group Trading Up 9.9 %

Shares of REPL opened at $13.02 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The stock has a market cap of $890.83 million, a PE ratio of -4.27 and a beta of 1.28. The stock’s 50-day moving average is $12.18 and its two-hundred day moving average is $11.28.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. Equities analysts forecast that Replimune Group will post -2.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Point72 DIFC Ltd bought a new stake in shares of Replimune Group during the 2nd quarter valued at about $57,000. Erste Asset Management GmbH bought a new position in shares of Replimune Group during the third quarter valued at approximately $133,000. China Universal Asset Management Co. Ltd. raised its position in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after purchasing an additional 5,926 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after purchasing an additional 6,748 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Replimune Group during the 3rd quarter valued at approximately $222,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.